EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

Clinical study to investigate the adjuvant role of Pentoxifylline in patients with Parkinson's disease: A randomized controlled study

Mohannad O Khrieba, Sahar K Hegazy, Wessam Fathi Mohammed, Sahar M El-Haggar

International Immunopharmacology · 2025-05 · 156 · 114689

DOI: 10.1016/j.intimp.2025.114689 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift International Immunopharmacology, 2025-05. Verfasst von Mohannad O Khrieba und 3 weiteren Autor:innen. Beteiligte Einrichtung: Pharmacy Practice Department, Faculty of Pharmacy, Horus University, New Damietta, Egypt. Electronic address: mkhrieba@horus.edu.eg. Hauptthemen laut MEDLINE: Pentoxifylline, Parkinson Disease, Neuroprotective Agents, Anti-Inflammatory Agents. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 90 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Parkinson's disease (PD) is a common neurodegenerative disease characterized by the loss of dopaminergic neurons in the par's compacta of the substantia nigra. A lot of studies have since been carried out on the neuroinflammation linked to the pathophysiology of PD, including elevated levels of proinflammatory cytokines. Preclinical studies proved the efficacy of pentoxifylline (PTX) in PD. AIM: To assess the neuroprotective and anti-inflammatory effects of PTX in patients with PD. METHODS: Sixtytwo Patients were randomly assigned to two groups (n1 = 30, and n2 = 32); the PTX group received conventional treatment for Parkinson's disease, levodopa/carbidopa, plus PTX 400 mg twice daily, whereas the control group received conventional treatment only. Every patient was assessed by a neurologist both at the start of treatment and six months thereafter. Every patient is evaluated using the Unified Parkinson's disease rating scale (UPDRS). Adenosine monophosphate activated protein kinase (AMPK), reduced glutathione (GSH), high mobility group box protein (HMGB1), and mammalian target of rapamycin (mTOR) were measured both before and after therapy. The statistical analysis within and between groups was evaluated using direct and indirect t-tests, respectively. RESULTS: The PTX group revealed a statistically significant decrease in the level of assessed variables as followed: mTOR (p = 0.037), HMGB-1 (p = 0.029), and a significant increase in GSH (p = 0.016) and AMPK (p = 0.027), when compared to the control group. Additionally, the PTX group had a significantly reduced UPDRS. (p < 0.05). CONCLUSION: PTX may be suggested as a promising adjuvant anti-inflammatory medication for Parkinson's disease treatment. CLINICAL TRIAL IDENTIFIER: NCT05962957.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PentoxifyllineParkinson DiseaseNeuroprotective AgentsAnti-Inflammatory AgentsAntiparkinson AgentsHumansMaleFemaleMiddle AgedAgedLevodopaCarbidopaTOR Serine-Threonine KinasesHMGB1 ProteinGlutathioneAMP-Activated Protein KinasesDrug CombinationsTreatment Outcome

Stichwörter der Autor:innen

HMGB-1NeuroinflammationOxidative stressPTXParkinson's disease

Substanzen

PentoxifyllineLevodopaNeuroprotective AgentsCarbidopacarbidopa, levodopa drug combinationTOR Serine-Threonine KinasesHMGB1 ProteinAnti-Inflammatory AgentsMTOR protein, humanGlutathione

Autor:innen und Institutionen

  • Pharmacy Practice Department, Faculty of Pharmacy, Horus University, New Damietta, Egypt. Electronic address: mkhrieba@horus.edu.eg.
  • Pharmacy Practice Department, Faculty of Pharmacy, Horus University, New Damietta, Egypt; Clinical Pharmacy Department, Faculty of Pharmacy, Tanta University, El-Guiesh Street, El-Gharbia Government, Tanta 31527, Egypt.
  • Neurology Department, Faculty of Medicine, Mansoura University, Mansoura, Egypt.
  • Clinical Pharmacy Department, Faculty of Pharmacy, Tanta University, El-Guiesh Street, El-Gharbia Government, Tanta 31527, Egypt.

Zitieren

APA

Khrieba, M. O., Hegazy, S. K., Mohammed, W. F., & El-Haggar, S. M. (2025). Clinical study to investigate the adjuvant role of Pentoxifylline in patients with Parkinson's disease: A randomized controlled study. International Immunopharmacology, 156, 114689. https://doi.org/10.1016/j.intimp.2025.114689

Vancouver

Khrieba MO, Hegazy SK, Mohammed WF, El-Haggar SM. Clinical study to investigate the adjuvant role of Pentoxifylline in patients with Parkinson's disease: A randomized controlled study. International Immunopharmacology. 2025;156:114689. doi:10.1016/j.intimp.2025.114689

BibTeX
@article{Khrieba2025,
  author = {Khrieba, Mohannad O and Hegazy, Sahar K and Mohammed, Wessam Fathi and El-Haggar, Sahar M},
  title = {Clinical study to investigate the adjuvant role of Pentoxifylline in patients with Parkinson's disease: A randomized controlled study},
  journal = {International Immunopharmacology},
  year = {2025},
  volume = {156},
  pages = {114689},
  doi = {10.1016/j.intimp.2025.114689}
}
Kostenlos starten →